98 related articles for article (PubMed ID: 2313981)
1. Ticlopidine prevents renal disease progression in rats with reduced renal mass.
Zoja C; Perico N; Bergamelli A; Pasini M; Morigi M; Dadan J; Belloni A; Bertani T; Remuzzi G
Kidney Int; 1990 Mar; 37(3):934-42. PubMed ID: 2313981
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.
Zoja C; Perico N; Corna D; Benigni A; Gabanelli M; Morigi M; Bertani T; Remuzzi G
J Am Soc Nephrol; 1990 Nov; 1(5):799-807. PubMed ID: 2133429
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease.
Zoja C; Benigni A; Livio M; Bergamelli A; Orisio S; Abbate M; Bertani T; Remuzzi G
Am J Pathol; 1989 May; 134(5):1027-38. PubMed ID: 2497648
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation.
Purkerson ML; Joist JH; Yates J; Valdes A; Morrison A; Klahr S
Proc Natl Acad Sci U S A; 1985 Jan; 82(1):193-7. PubMed ID: 3855542
[TBL] [Abstract][Full Text] [Related]
5. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Tu X; Chen X; Xie Y; Shi S; Wang J; Chen Y; Li J
J Am Soc Nephrol; 2008 Jan; 19(1):77-83. PubMed ID: 18045851
[TBL] [Abstract][Full Text] [Related]
7. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
Hirata Y; Takiguchi Y; Wada K; Matsuno H; Umemura K; Uematsu T; Nakashima M
Eur J Pharmacol; 1993 Feb; 231(3):421-5. PubMed ID: 8449234
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Umemura K; Kawai H; Ishihara H; Nakashima M
Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
[TBL] [Abstract][Full Text] [Related]
11. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
12. Effect of ticlopidine on the evolution of renal disease in rats with reduced renal mass.
Zoja C; Perico N; Bertani T; Remuzzi G
Contrib Nephrol; 1990; 81():279-88. PubMed ID: 2093508
[No Abstract] [Full Text] [Related]
13. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
Furci L; Fitzgerald DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effect of thromboxane A2 receptor blockade in genetically hypertensive rats of the Lyon strain.
Geoffroy J; Benzoni D; Sassard J
J Hypertens Suppl; 1989 Dec; 7(6):S272-3. PubMed ID: 2534414
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of platelet aggregation by a new agent, Ticlopidine.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
[TBL] [Abstract][Full Text] [Related]
17. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
Di Minno G; Cerbone AM; Mattioli PL; Turco S; Iovine C; Mancini M
J Clin Invest; 1985 Feb; 75(2):328-38. PubMed ID: 3156146
[TBL] [Abstract][Full Text] [Related]
18. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
White BP; Sullivan AT; Lumley P
Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study.
Somova L
Methods Find Exp Clin Pharmacol; 1996 Jun; 18(5):309-13. PubMed ID: 8817465
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
